Translational research needs industry
One of EB-ResNet's main strategic aims is to establish partnerships to develop and deliver treatments for people living with EB. Fortunately more clinical trials than ever are being registered. In order to bring them to EB patients, partnership is needed.
EB-ResNet welcomes inquiries about the eligibility of industry proposals from biopharma and health-technology companies relating to preclinical research and clinical trials. Various forms of funding from co-funding to research grants with defined ROI terms, may be considered. While bespoke terms may be negotiated on a case-by-case basis, the principles of our terms and conditions of funding, progress reporting, and forms of revenue sharing will apply.
Project scope 'Industry co-funding'
- Translational research and treatment development for EB
- Project is in late preclinical to clinical stage
- Lead applicant: industry partners
- Project duration: no limitations
- Funding: up to EUR 250,000.00
Like the application process for Ad-hoc grants, the application process has two steps. Informal application is done via a letter of interest (LOI) to email@example.com.
You will be informed whether your project fits into our funding scheme and if so, sent a link to our Grant Management online Application form.
Note that the project leader must have a contract of employment with the lead host institution/organisation at least for the time of the project period. Project lead salary and overheads/admin costs are not eligible. All research projects handed in have to be hypothesis driven and have to meet at least one of the EB-ResNet's research priorities. EB-ResNet does not fund any service provision (i.e. clinical testing) costs.
For applications from research consortia involving industry, but led by an academic partner, additional side-agreements may be required. Please also note our terms & conditions including revenue sharing before submitting any application.
Knowledge exchange and partnership
Active partnership with industry is needed more than ever to push the development of treatment forward. This can be achieved not only via direct industry co-funding but also via knowledge-sharing. We are convinced that the involvement of patients and patient organisations at a very early stage in translational research is crucial. We can provide you knowledge abeout EB and patients' perspectives and needs, and help optimise clinical trial design right from the start.